Eli Lilly’s Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment

All NewsNovember 7, 2025

Eli Lilly’s eloralintide cut body weight by up to 20% in a Phase 2 trial, showing strong efficacy and potential to advance obesity treatment.

Latest Ratings for LLY

DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022MizuhoMaintainsBuy Jan 2022Morgan StanleyMaintainsOverweight

View More Analyst Ratings for LLY

View the Latest Analyst Ratings

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent